Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ghelardini

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
British Journal of Pharmacology|March 11, 2018
In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505N Dietis, H Niwa, R Tose, et al.
Biochemical Pharmacology|July 31, 2023
Persulfidation of mitoKv7.4 channels contributes to the cardioprotective effects of the H<sub>2</sub>S-donor Erucin against ischemia/reperfusion injuryL Testai, R Montanaro, L Flori, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 12, 2025
The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effectsA Toti, E Lucarini, V Ferrara, et al.
Pharmacological Research|October 3, 2013
The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunctionA Martelli, L Testai, M Anzini, et al.
Current Medicinal Chemistry|March 25, 2011
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agentsM Biava, G C Porretta, G Poce, et al.
Gut Microbes|September 15, 2023
Disruption of the microbiota-gut-brain axis is a defining characteristic of the α-Gal A (-/0) mouse model of Fabry diseaseC Delprete, R Rimondini Giorgini, E Lucarini, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
British Journal of Pharmacology|March 11, 2018
In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505N Dietis, H Niwa, R Tose, et al.
Biochemical Pharmacology|July 31, 2023
Persulfidation of mitoKv7.4 channels contributes to the cardioprotective effects of the H<sub>2</sub>S-donor Erucin against ischemia/reperfusion injuryL Testai, R Montanaro, L Flori, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 12, 2025
The dual role of VEGF-A in a complex in vitro model of oxaliplatin-induced neurotoxicity: Pain-related and neuroprotective effectsA Toti, E Lucarini, V Ferrara, et al.
Pharmacological Research|October 3, 2013
The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunctionA Martelli, L Testai, M Anzini, et al.
Current Medicinal Chemistry|March 25, 2011
Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agentsM Biava, G C Porretta, G Poce, et al.
Gut Microbes|September 15, 2023
Disruption of the microbiota-gut-brain axis is a defining characteristic of the α-Gal A (-/0) mouse model of Fabry diseaseC Delprete, R Rimondini Giorgini, E Lucarini, et al.
Pageof 12